SLAMF1 is expressed and secreted by hepatocytes and the liver in nonalcoholic fatty liver disease
Oscar Gómez, Shripa Amatya, Lilly Kamberov, Hemangini A. Dhaibar, Pranshu Khanna, Oren Rom, Arif Yurdagul, A. Wayne Orr, Kelly Nunez, Paul Thevenot, Ari Cohen, Hrishikesh Samant, J. Steven Alexander, Emma Burgos‐Ramos, Adrián Chapa‐Rodríguez, Diana Cruz‐Topete
2022American Journal of Physiology-Gastrointestinal and Liver Physiology12 citationsDOIOpen Access PDF
Abstract
This study identified for the first time SLAMF1 as a mediator of hepatocyte death in nonalcoholic fatty liver disease (NASH) and as a marker of NASH in humans. There are no pharmacological treatments available for NASH, and diagnostic tools are limited to invasive liver biopsies. Therefore, since SLAMF1 levels correlate with disease progression and SLAMF1 mediates cytotoxic effects, this protein can be used as a therapeutic target and a clinical biomarker of NASH.
Topics & Concepts
Nonalcoholic fatty liver diseaseNonalcoholic steatohepatitisHepatocyteDiseaseMediatorBiomarkerFatty liverLiver diseaseCancer researchBiologyMedicineCell biologyBiochemistryInternal medicineIn vitroLiver Disease Diagnosis and TreatmentLiver Disease and TransplantationEndoplasmic Reticulum Stress and Disease